BioWorld Asia

July 2, 2008

View Archived Issues

EU Drug Development Slowdown Due to Biotech Complexity?

BRUSSELS, Belgium - There is a slowdown in the volume of useful new drugs on the European market, and biotech is in part to blame, according to the leading European pharmaceutical industry association. (BioWorld International) Read More

Alizyme, Norgine Team Up in $67M Marketing Deal

Read More

Blood Vessel Growth Blocker Could Be Used to Starve Tumors

Read More

Short of Money and Time, Ardana Biosciences Dies

Read More

Patent Infringement Claim Filed Against Oxford Biomedica

Read More

Oxford Profs Found Celleron to Scope Tumor Sensitivity

Read More

Immutep Reports Positive Results from LAG-3 Immunotherapy

Read More

Ascenion Adds Protectimmun to its Investment Portfolio

Read More

Other News To Note

Read More